Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor Synthesis of Natural Org

Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor Synthesis of Natural Org

A. J. DELMONTE* ET AL. (BRISTOL-MEYERS SQUIBB COMPANY, NEW BRUNSWICK, USA) Category The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor Synthesis of Natural Org. Process Res. Dev. 2018, 22, 1393–1408. Products and Potential Drugs Synthesis of Beclabuvir Key words beclabuvir N2 OMe asymmetric Ph O cyclopropanation O Ph3P=CH2 O (1.05 equiv) OMe C (ca. 1.0 equiv) arylation OMe MeO OMe H THF, 25 °C, 3 h Rh2(S-DOSP)4 Heck reaction Al O chromatography Br (0.002 equiv) Br 2 3 Ph Br 55% (372 mol scale) heptane, r.t., 2 h rhodium B 94% (93 mol scale) A D mp not reported palladium 83% ee 1. O3/CH2Cl2, –60 °C 2. NaBH4 (3.3 equiv) MeOH, –10 °C, 2 h O Ph NH2 1. TMSCl (3.0 equiv) O 3. LiOH (4.0 equiv) E EtOH, 64 °C, 5.5 h Ph NH2 THF–MeOH–H2O EtO OMe HO OMe 2. TsCl (1.0 equiv) 4. E (0.96 equiv) DABCO (1.38 equiv) 2-PrOH–H O, 75–25 °C OTs OH 2 Br PhMe, 0–20 °C Br 56.5% (64.6 mol scale) G 56.8 mol scale F mp not reported 99.6% ee O O O H S N O Me2N N H EtO 1. Pd(OAc)2 (0.05 equiv) OMe Cy3P•HBF4 (0.1 equiv) O O O KHCO3 (4.0 equiv) H (1.06 equiv) DMAc–PhMe, 125 °C S N Br Me2N N NaHMDS (1.9 equiv) H 2. KOH (2.9 equiv), THF–DMF, 60 °C; DMAc–H2O, 40 °C cryst ex 2-PrOH–heptane 3. aq HCl to pH 1–3 47% from G 4. KOEt in EtOH to pH 7.0–8.0 I 85% (64.8 mol scale) mp not reported N • HCl Me N O • 2 HCl KO O Me N • 0.5 DMAc NH O O O O K (1.22 equiv) O O S N S N Me2N N EDCI (1.23 equiv) Me2N N H H OMe HATU (1.22 equiv) OMe DIPEA (3.2 equiv) MeCN, 5–20 °C, 16 h then HCl (1.04 equiv) Beclabuvir hydrochloride J 89.5% (3.32 mol scale) mp not reported mp not reported Significance: Beclabuvir (Ximency®, BMS-791325) Comment: Key steps in the large-scale synthesis This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. is a non-nucleoside, nonstructural protein 5B (NS5B) depicted include (1) the rhodium-catalyzed asym- RNA polymerase inhibitor that was approved in Ja- metric cyclopropanation of styrene C (94% yield, pan for use in combination with Asunaprevir and 83% ee) and (2) the construction of the seven- Daclatasvir for the treatment of hepatitis C virus in- membered ring by an intramolecular Heck reac- fection. tion. Beclabuvir was prepared in twelve linear steps with five isolations in 8% overall yield. SYNFACTS Contributors: Philip Kocienski Synfacts 02012019, 15(01), 0003 Published online: 14.12.20181861-19581861-194X DOI: 10.1055/s-0037-1611441; Reg-No.: K07118SF ©Georg Thieme Verlag Stutgart · New York 2019 © Georg Thieme Verlag Stuttgart · New York 3.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    1 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us